Table 1.
Demographics, clinical staging, treatments and FOXM1 protein expression in gastric tissue
| Normal gastric tissue | Gastric adenocarcinoma | |
|---|---|---|
| Number of cases | 47 | 79 |
| Male | 30 (64 %) | 46 (58 %) (p = 0.87) |
| Age | 69 ± 9 | 70 ± 11 (p = 0.94) |
| Pathological differentiation | ||
| Poor | 40 (51) | |
| Moderate | 28 (35) | |
| Well | 9 (11) | |
| Missing | 2 (3) | |
| Depth of invasion | ||
| T1 | 8 (10) | |
| T2 | 22 (28) | |
| T3 | 42 (53) | |
| T4 | 5 (6) | |
| Missing | 1 (1) | |
| Metastatic disease | ||
| Local (N) | 53 (67) | |
| Distant (M) | 4 (5) | |
| AJCC 2010 stage | ||
| 1 | 15 (19) | |
| 2 | 22 (28) | |
| 3 | 31 (39) | |
| 4 | 9 (11) | |
| Missing | 1 (1) | |
| Treatment | ||
| Surgery | 65 (82) | |
| Surgery and chemotherapy | 5 (6) | |
| Chemotherapy | 6 (8) | |
| Palliative care | 2 (3) | |
| Missing | 1 (1) | |
| FOXM1 mRNA expression | ||
| Positive expression | 26 (55) | 56 (71) (p = 0.001) |
| High positive expression | 1 (2) | 23 (29) (p = 0.001) |
The number of cases is illustrated, percentages are in brackets. The number of patients with missing data is indicated. Positive expression was taken as an immunohistochemistry score of > 90 and High positive expression was taken as an immunohistochemistry score > 150. P values calculated by Chi2 test are indicated